Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7438487 | 0.98 | NFE2L2 (0.47) | NFE2L2LTA4HMEN1KMT2AHRH3 | |
| SCHEMBL7446113 | 0.89 | MEN1 (0.49) | MEN1KMT2AALDH1A1HTR6GFER | |
| SCHEMBL23314833 | 0.88 | GBA1 (0.50) | NFE2L2MEN1KMT2A | |
| SCHEMBL10229753 | 0.83 | LTA4H (0.46) | LTA4HHRH3LOXL2 | |
| SCHEMBL21767250 | 0.81 | ALDH1A1 (0.44) | NFE2L2LTA4HMEN1KMT2AHRH3 | |
| SCHEMBL40077 | 0.81 | MEN1 (0.44) | MEN1KMT2AALDH1A1HTR6GFER | |
| Hydrochloric Acid SCHEMBL507883 | 0.81 | LTA4H (0.45) | LTA4HHRH3LOXL2 | |
| Ammonia Solution, Strong SCHEMBL14343979 | 0.79 | MEN1 (0.43) | MEN1KMT2AALDH1A1HTR6GFER | |
| SCHEMBL2627277 | 0.79 | MEN1 (0.43) | MEN1KMT2AALDH1A1HTR6GFER | |
| SCHEMBL1264017 | 0.79 | GBA1 (0.66) | MEN1KMT2AHRH3ALDH1A1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003793-A | Polyamide-imide film and preparation method thereof | 株洲时代华昇新材料技术有限公司 | 2023-04-25 | — | — | CN | claimed |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2023081637-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-111133019-A | Block copolymer, resin composition, coating film, resin film, OLED element, light-emitting device, and method for producing block copolymer | 捷恩智株式会社 | 2020-05-08 | — | — | CN | disclosed |
| CN-106946741-B | A kind of preparation method of dicyclohexyl methyl hydride diisocyanate | 万华化学集团股份有限公司 | 2018-12-07 | — | — | CN | disclosed |
| CN-106946741-A | A kind of preparation method of dicyclohexyl methyl hydride diisocyanate | 万华化学集团股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1224170-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma KG (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | NFE2L2 1948/4885LTA4H 3854/4885MEN1 3601/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | NFE2L2 1898/4885LTA4H 4049/4885MEN1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.